LV10051B - Method for producing of lyophilized yphosphamide - Google Patents

Method for producing of lyophilized yphosphamide Download PDF

Info

Publication number
LV10051B
LV10051B LVP-92-174A LV920174A LV10051B LV 10051 B LV10051 B LV 10051B LV 920174 A LV920174 A LV 920174A LV 10051 B LV10051 B LV 10051B
Authority
LV
Latvia
Prior art keywords
bis
die
und
der
ifosfamid
Prior art date
Application number
LVP-92-174A
Other languages
English (en)
Latvian (lv)
Other versions
LV10051A (lv
Inventor
Sauerbier Dieter
Damann Uwe-Peter
Isaac Otto
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of LV10051A publication Critical patent/LV10051A/xx
Publication of LV10051B publication Critical patent/LV10051B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Indole Compounds (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-92-174A 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide LV10051B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (2)

Publication Number Publication Date
LV10051A LV10051A (lv) 1994-05-10
LV10051B true LV10051B (en) 1995-06-20

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-92-174A LV10051B (en) 1986-10-31 1992-10-27 Method for producing of lyophilized yphosphamide

Country Status (25)

Country Link
EP (1) EP0265812B1 (sv)
JP (1) JPS63159319A (sv)
KR (1) KR900003491B1 (sv)
AT (1) ATE55250T1 (sv)
AU (1) AU598602B2 (sv)
CA (1) CA1314231C (sv)
DD (1) DD262582A5 (sv)
DE (1) DE3764235D1 (sv)
DK (1) DK169308B1 (sv)
EG (1) EG18333A (sv)
ES (1) ES2017982B3 (sv)
FI (1) FI87140C (sv)
GE (1) GEP19971025B (sv)
GR (1) GR3000708T3 (sv)
HU (1) HU197987B (sv)
IL (1) IL84312A (sv)
IN (1) IN168119B (sv)
LV (1) LV10051B (sv)
MX (1) MX8958A (sv)
NO (1) NO873860L (sv)
PT (1) PT86032B (sv)
RU (1) RU1836079C (sv)
UA (1) UA11075A (sv)
YU (1) YU197387A (sv)
ZA (1) ZA878183B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
ES2253877T3 (es) * 1998-03-03 2006-06-01 SHIONOGI & CO., LTD. Composiciones farmaceuticas que contienen el inhibidor de fosfolipasa((3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil)-1h-indol-4-il)oxi)acetato de sodio.
US20050272698A1 (en) * 2002-09-05 2005-12-08 Daftary Gautam V Liquid stable composition of oxazaphosphorine with mesna
KR101066181B1 (ko) * 2002-12-02 2011-09-20 바라트 쎄럼스 앤드 백신스 리미티드 비경구 투여용 아이포스파마이드 조성물 및 이의 제조방법
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
PL2071917T3 (pl) * 2006-09-29 2013-04-30 Infa Sa System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
WO2016087001A1 (en) * 2014-12-04 2016-06-09 Huawei Technologies Co., Ltd. Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
PT86032A (de) 1987-11-01
EP0265812B1 (de) 1990-08-08
NO873860L (no) 1988-05-02
NO873860D0 (no) 1987-09-15
FI874727A (fi) 1988-05-01
DK569687D0 (da) 1987-10-30
LV10051A (lv) 1994-05-10
EP0265812A1 (de) 1988-05-04
FI87140C (sv) 1992-12-10
AU598602B2 (en) 1990-06-28
ATE55250T1 (de) 1990-08-15
EG18333A (en) 1993-12-30
YU197387A (en) 1988-12-31
GR3000708T3 (en) 1991-10-10
KR880004814A (ko) 1988-06-27
JPH0543684B2 (sv) 1993-07-02
HUT44932A (en) 1988-05-30
AU8052987A (en) 1988-05-05
DE3764235D1 (de) 1990-09-13
ZA878183B (en) 1988-05-02
UA11075A (uk) 1996-12-25
IL84312A (en) 1991-11-21
DD262582A5 (de) 1988-12-07
CA1314231C (en) 1993-03-09
ES2017982B3 (es) 1991-03-16
DK569687A (da) 1988-05-01
GEP19971025B (en) 1997-04-06
PT86032B (pt) 1990-08-31
DK169308B1 (da) 1994-10-10
FI874727A0 (fi) 1987-10-27
MX8958A (es) 1993-12-01
IL84312A0 (en) 1988-03-31
JPS63159319A (ja) 1988-07-02
IN168119B (sv) 1991-02-09
FI87140B (fi) 1992-08-31
KR900003491B1 (ko) 1990-05-21
HU197987B (en) 1989-07-28
RU1836079C (ru) 1993-08-23

Similar Documents

Publication Publication Date Title
DE69617945T2 (de) Pharmazeutische zubereitungen, auf der basis von pflanzlichen etherischen ölen für die verwendung im menschlichen oder veterinären medizinischem bereich
DE68913075T2 (de) Stabilisiertes Arzneimittel und Verfahren zu dessen Herstellung.
LV10051B (en) Method for producing of lyophilized yphosphamide
DE3407823C2 (sv)
DE3909707A1 (de) Arzneimittel, geeignet zur einwirkung auf herz und kreislauf
EP0617958A1 (en) Pharmaceutical composition having anti-alcohol, radioprotecting and anti-choleraic activity and stimulating energy metabolism, stomach mucous membrane acid-generation and secretion functions
DE3638124C2 (de) Neue pharmazeutische Verwendung von Ebselen
DE1767163C3 (de) Blutdrucksenkendes Arzneimittel
DE2947646C2 (de) Substanz mit Interferon induzierender Aktivität, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69718422T2 (de) Pflanzlicher nahrungszusatz zum desodorieren von stuhl und urin
DE3129123A1 (de) "arzneimittel zur senkung des cholesterinblutspiegels"
DE2009342C3 (de) Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
Brändle Bedeutung der kolonialen Komponenten für die Bildung und Differenzierung der Medusen vonPodocoryne carnea M. Sars
Köllner et al. Psychotherapeutische Interventionen vor und nach Organtransplantation
DE2911332A1 (de) Antikomplementaere mittel, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
CH640244A5 (en) Biologically active substance
DE2729903A1 (de) Antithrombosemittel
DE905882C (de) Verfahren zur Gewinnung von Giften und Gegengiften zur Heilbehandlung entsprechender Infektionskrankheiten
DE60216518T2 (de) Bioaktive hexan fraktion aus vetiveria zizanioides
Drews et al. Granzen der Chemotherapie
DE3043291A1 (de) Vakzine gegen keuchhusten
Heite Zur Pharmakologie des Griseofulvins
DE1001803C2 (de) Verfahren zur Herstellung eines Arzneimittels mit antituberkuloeser Aktivitaet
Gording Klinische und experimentelle Untersuchungen über die Aetiologie des Gelenk-und Muskel-rheumatismus mit besondrer Berücksichtigung der tonsillogenen Infektion
Kurz Das weiße Blutbild bei der Kolik des Pferdes in Abhängigkeit vom Krankheitsverlauf